Sep 2026· Ankara Üniversitesi Tıp Fakültesi Mecmuası· Vol 79, pp. 321-328· 0 citations· 13 references
TL;DR
Findings suggest that inhibition of mitochondrial fission may enhance the antiproliferative effect of TMZ in GBM cells, and targeting mitochondrial dynamics may represent a potential therapeutic strategy for overcoming treatment resistance.
Abstract
Aim: Glioblastoma multiforme (GBM) is characterized by poor prognosis and therapeutic resistance. Mitochondrial dynamics, particularly mitochondrial fission regulated by DRP1, play a critical role in apoptosis. This study aimed to investigate the effect of mitochondrial fission inhibition on apoptosis in U87 wild-type cells and to evaluate the potential synergistic therapeutic effect of combining mitochondrial fission inhibition with temozolomide (TMZ).Materials and methods: The cytotoxic effects and IC₅₀ values of Mdivi-1 and TMZ were determined by a 72-hour MTT assay. Based on these results, 50 μM Mdivi-1 was selected for combination treatment with 50 μM TMZ, and the expression levels of DRP1, FIS1, BAX, and BCL2 were analyzed by qRT-PCR.Results: Mitochondrial fission inhibition significantly reduced cell viability (p < 0.05). Combination treatment with Mdivi-1 and TMZ further decreased cell viability compared with the control group. qRT-PCR analysis revealed a significant decrease in BCL2 mRNA expression following Mdivi-1 treatment,whereas changes in DRP1, FIS1, and BAX expression were not statistically significant.Conclusion: These findings suggest that inhibition of mitochondrial fission may enhance the antiproliferative effect of TMZ in GBM cells. Targeting mitochondrial dynamics may represent a potential therapeutic strategy for overcoming treatment resistance; however, further studies are required to clarify the underlying molecular mechanisms.
Glioblastoma multiforme (GBM) is an aggressive central nervous system tumor associated with poor prognosis and resistance to conventional therapies. This study investigated the cytotoxic and mechanistic effects of the selective serotonin reuptake inhibitor fluoxetine (FLT), alone and in combination with the alkylating...
Berrin Tuğrul, Dilan Odabaş, Fatih Çöllü· Journal of Research in Pharm...· 0 citations
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults and remains associated with poor prognosis despite multimodal treatment. The identification of clinically approved drugs with novel antitumor activities has emerged as a promising strategy for accelerating therapeutic development. Rasagiline, an...
Guven Akçay, O. Anakok, M. Ozkaraca et al.· Scientific Reports· 0 citations
Triple-negative breast cancer (TNBC) is highly aggressive and lacks targeted therapies. This study investigated the anti-cancer mechanisms of sinapaldehyde (SNAH). The biological effects of SNAH were evaluated in vitro using MDA-MB-231 TNBC cells. Cellular responses, including autophagy, mitochondrial function, apoptos...
H. Kumarasinghe, Ducdat Le, Ji-Hyang Kim et al.· International Journal of Mol...· 0 citations
Background: Glioblastoma (GBM) is the most aggressive primary brain tumor and remains difficult to treat because of its highly invasive behavior and resistance to conventional therapies despite surgery, radiotherapy, and chemotherapy. Sodin 5, a novel type-1 ribosome-inactivating protein (RIP), inhibits protein synthes...
Veronica Russo, Sara Ragucci, Miriam Russo et al.· Toxins· 0 citations
Hypoxia is a key contributor to chemoresistance in glioblastoma (GBM), partly through the activation of nuclear factor erythroid 2-related factor 2 (Nrf2)-dependent cellular stress responses and mitochondrial adaptive programs. The present study investigated Nrf2 signaling in hypoxia-associated resistance to temozolomi...
Pinpat Tripatara, T. Onkoksoong, Sunisa Prasopporn et al.· Biomedical Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.